10x Genomics (TXG) Change in Receivables (2018 - 2026)

10x Genomics has disclosed Change in Receivables across 9 years of filings, most recently posting -$18.1 million for Q1 2026.

• Change in Receivables for Q1 2026 came in at -$18.1 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $16.7 million (up 587.48% YoY), and the FY2025 annual result was $34.9 million, up 229.4% from the prior year.
• Change in Receivables came in at -$18.1 million for Q1 2026 at 10x Genomics, down from -$17.3 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $90.1 million in Q3 2025 to a low of -$37.9 million in Q2 2025.
• The 5-year median for Change in Receivables is -$209500.0 (2022), against an average of $1.2 million.
• Across the five-year window, Change in Receivables jumped 3383.84% in 2023 and tumbled 30979.51% in 2025, its largest moves.
• 10x Genomics' Change in Receivables stood at $20.6 million in 2022, then sank by 46.78% to $11.0 million in 2023, then plunged by 60.18% to $4.4 million in 2024, then tumbled by 496.66% to -$17.3 million in 2025, then retreated by 4.59% to -$18.1 million in 2026.
• The last three Change in Receivables figures came in at -$18.1 million (Q1 2026), -$17.3 million (Q4 2025), and $90.1 million (Q3 2025), per Business Quant data.